Investigation Questions Drug's Approval for Agitation in AD

The agency defended approval of brexpiprazole (Rexulti) for the treatment of agitation, saying the antipsychotic fills an unmet medical need.
Medscape Medical News

source https://www.medscape.com/viewarticle/995697?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost